(Stock Code: 2407) （股 份 代 號：2407） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders: Gaush Meditech Ltd (the "Company") — Notice of publication of 2024 Annual Report, Circular, Proxy Form and Notice of Annual General Meeting (the "Current Corporate Communication") Gaush Meditech Ltd 高視醫療科技有限公司 (Incorporated in the Cayman Islands with limited liability) （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） — 刊發2024年年度報告、通函、委任表格及股東週年大會通告（「本次公司通訊」） 本公司的本次公司通訊之中文、英文版本已分別上載於本公司網站( www.gaush.com )及香港聯合交易所有限公司（「聯交所」）之網 站( www.h ...

Gaush Meditech Ltd 高視醫療科技有限公司 (Incorporated in the Cayman Islands with limited liability) （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） (Stock Code: 2407) （股 份 代 號：2407） NOTIFICATION LETTER 通知信函 Notes: 各位非登記持有人 （附註1） ： 高視醫療科技有限公司（「本公司」） — 刊發2024年年度報告、通函及股東週年大會通告（「本次公司通訊」） Dear Non-registered Holder(s) (Note 1) : Gaush Meditech Ltd (the "Company") — Notification of publication of 2024 Annual Report, Circular and Notice of Annual General Meeting (the "Current Corporate Communication") The English and Chinese versions o ...

Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 股東週年大會通告 茲通告高視醫療科技有限公司（「本公司」）謹訂於2025年5月29日（星期四）下午三時 正假座中國北京市東城區東直門南大街11號中匯廣場A座1901室舉行股東週年大會（「股 東週年大會」），以處理下列事項： 普通決議案 – 1 – 1. 省覽及採納本公司截至2024年12月31日止年度的經審核綜合財務報表、董事會報 告及核數師報告。 2. (a) 重選以下退任的本公司董事（「董事」）： (i) 重選高鐵塔先生為執行董事； (ii) 重選劉新偉先生為執行董事； (iii) 重選David Guowei Wang博士為非執行董事；及 (b) 授權董事會（「董事會」）釐定董事的薪酬。 3. 續聘安永會計師事務所為本公司核數師，並授權董事會釐定其酬金。 – 2 – 4. 考慮及酌情通過（不論有否修訂）下列決議案為普通決議案： (A) 「動議： (i) 在下文第(iii)段的規限下，一般及無條件批准董事於有關期間（定義見 下文）內行使本公司一切 ...

此乃要件 請即處理 閣下如對本通函或應採取的行動有任何疑問，應諮詢 閣下的股票經紀或其他註冊證 券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有高視醫療科技有限公司股份，應立即將本通函及隨附的 代表委任表格送交買主或承讓人，或經手買賣或轉讓的銀行、股票經紀或其他代理商， 以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部分 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 建議 發行股份及購回股份的一般授權、 重選退任董事、 宣派末期股息 及 股東週年大會通告 高視醫療科技有限公司謹訂於2025年5月29日（星期四）下午三時正假座中國北京市東城 區東直門南大街11號中匯廣場A座1901室舉行股東週年大會，大會通告載於本通函第21 至26頁。隨函亦附奉股東週年大會適用的代表委任表格。該代表委任 ...

Financial Performance - The company's revenue for the year ended December 31, 2024, was RMB 1,428.4 million, an increase of 1.6% compared to RMB 1,406.2 million for the year ended December 31, 2023[11]. - The net profit for the year ended December 31, 2024, was RMB 88.5 million, a decrease of 48.8% from RMB 172.9 million in 2023[11]. - Basic earnings per share for the year ended December 31, 2024, were RMB 0.63, down from RMB 1.17 in 2023[11]. - The board proposed a final dividend of HKD 0.3 per share for the year ended December 31, 2024, compared to HKD 1.1 per share in 2023[11]. - The company's gross profit for the same period was RMB 663.4 million, which is a decrease of 4.1% year-over-year[21]. - Sales cost rose by 7.1% from RMB 714.6 million to RMB 765.0 million, slightly outpacing revenue growth due to rising material costs and procurement prices[41]. - Gross profit decreased by 4.1% from RMB 691.6 million to RMB 663.4 million, with gross margin dropping from 49.2% to 46.4%[42]. - Other income and gains fell by 41.3% from RMB 45.0 million to RMB 26.4 million, primarily due to foreign exchange losses[43]. - The company recorded a net profit of RMB 88.5 million for the year ending December 31, 2024, down from RMB 172.9 million for the previous year[51]. Product Development and Innovation - The company has successfully launched three domestically developed single-focus intraocular lenses and is currently developing high-end domestic intraocular lenses[13]. - A new generation of dry eye examination products has been registered and officially launched for sale[13]. - The company is advancing AI diagnostic screening applications and smart manufacturing technologies in its product development[13]. - The company achieved MDR CE certification for its hydrophilic acrylic intraocular lens product line, marking a significant milestone[13]. - The company has established a "Global 4+2" R&D layout, with 265 R&D personnel, accounting for approximately 30% of total staff[28]. - R&D expenditure for the reporting period was RMB 78.4 million, representing 20.9% of proprietary product revenue, indicating a strong focus on innovation[28]. - The company aims to enhance its R&D capabilities, which accounted for 38.2% of the net proceeds allocation[119]. Market Expansion and Partnerships - The company has established exclusive distribution agreements with 16 out of 18 overseas brand partners, enhancing its product portfolio and market position[14]. - The company’s overseas business has expanded, participating in large-scale exhibitions with over 5,000 attendees and achieving MDR CE certification for its hydrophilic acrylic intraocular lens product line[33]. - The company’s products are now sold in 52 countries and regions, with its Roland products available in 33 countries[34]. - The company has established exclusive distribution agreements with 16 overseas brand partners, including a new partnership with South Korea's Sometech Inc. for 3D 4K digital ophthalmic surgical microscopes[31]. - The company aims to enhance its product offerings and expand its market presence in Asia and Europe, while optimizing management processes for improved efficiency[19]. Financial Position and Cash Management - As of December 31, 2024, the group's cash and cash equivalents amounted to RMB 421.4 million, a decrease of 31.9% from RMB 618.7 million as of December 31, 2023, primarily due to dividend payments of RMB 148.5 million and loan repayments of approximately RMB 109.7 million during the reporting period[64]. - The group's debt-to-asset ratio as of December 31, 2024, was 34.8%, down from 39.1% as of December 31, 2023[68]. - The group continues to maintain a strong cash flow and financial resources to support its operational and expansion plans[64]. - The group has implemented internal control measures to enhance cash management and reduce financial risks[64]. - The fair value financial assets decreased from RMB 175.6 million as of December 31, 2023, to RMB 97.7 million as of December 31, 2024, reflecting the company's focus on enhancing cash management efficiency and seeking high-return investment opportunities[52]. Employee and Management Structure - The total employee cost for the group for the year ended December 31, 2024, was RMB 375.2 million, compared to RMB 352.5 million for the year ended December 31, 2023, reflecting an increase of approximately 6.1%[140]. - The group had a total of 884 employees as of December 31, 2024, up from 869 employees as of December 31, 2023[140]. - The company emphasizes talent development and cultural construction as part of its strategic initiatives[80]. - The leadership team is well-educated, with degrees from prestigious institutions such as the University of Wisconsin-Madison and Peking University[81][88]. - The company has a strong focus on compliance and internal audit functions, overseen by Zhao Xinli as Chief Compliance Officer[79]. Governance and Compliance - The board consists of five executive directors, one non-executive director, and three independent non-executive directors, maintaining compliance with listing rules[194]. - The independent non-executive directors play a crucial role in providing unbiased opinions on the company's strategy and performance[197]. - The company has adopted a corporate governance code to ensure compliance and protect shareholder interests[187]. - The board has established three committees: audit, remuneration, and nomination, to oversee specific aspects of governance[193]. - The board confirmed the independence of all independent non-executive directors throughout the reporting period[133]. Shareholder Information - Major shareholders include GT HoldCo with 63,263,528 shares, representing 42.78% of the total issued share capital[161]. - OrbiMed Advisors III Limited and its affiliates collectively hold 18,039,426 shares, accounting for 12.20% of the total issued share capital[161]. - The company has maintained a minimum of 25% public shareholding throughout the reporting period[177]. - The company has sufficient financial resources to implement share repurchases while maintaining a sound financial position[165]. - The company repurchased a total of 82,500 shares during the reporting period, at a total cost of HKD 976,492, representing 0.056% of the total issued shares[165].

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 近日， 高视医疗 （02407.HK）全资附属公司北京高视远望科技有限责任公司所代理的德国 海德堡 （ Heidelberg）公司出品的 ANTERION 眼科检测仪（三合一眼前节多模影像诊断平台） 获得中国药监局 医疗器械注册证 ，该仪器集多项功能于一体，能提升眼科诊疗效率，丰富集团产品组合。 该产品自2024年起在美国上市，是一款 集生物测量仪、角膜地形图、前节OCT于一体 的多模影像诊断平 台，能够在屈光、角膜病、青光眼、视光等多个眼科亚专科领域发挥重要作用。在屈光手术中， ANTERION眼科检测仪能精准评估角膜上皮厚度和视觉质量，引导个性化切削 方案；在白内障手术中，结 合角膜地形图与生物测量数据，可降低术后屈光意外风险。 ANTERION 眼科检测仪运用 1300nm 波长的 SS-OCT 技术 ，具有穿透力强、扫描速度快、成像分辨率高 的特点，结合 动眼追踪（Eye-tracking）和光线追踪（Ray-tracing）技术 ，提供高效全面的眼前节诊 疗解决方案，一台设备即可完 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 角膜共聚焦顯微鏡取得國家醫療器械註冊證 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 本公告由高視醫療科技有限公司（「本公司」，連同其附公司統稱「本集團」）自 願作出，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於近日，本公司全資附屬公司高 視創新科技有限公司（「高視創新」）自主研發的型號為T3-600及T3-400的角膜共 聚焦顯微鏡取得由江蘇省藥品監督管理局批准的醫療器械註冊證。 該角膜共聚焦顯微鏡通過技術創新實現行業突破，成為國內同類設備中首款 兼具寬視場與高分辨率。該設備採用激光光源和斷層共焦掃瞄技術，將掃瞄視 場提升至600×600μm，光學分 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 高视医疗科技有限公司 | | 股份代號 | 02407 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度之末期股息 | | 公告日期 | 2025年3月26日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.3 HKD | | 股東批准日期 | 2025年5月29日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.3 HKD | | 匯率 | 1 HKD : 1 HKD ...

Financial Performance - The company's revenue for the year ended December 31, 2024, was RMB 1,428.4 million, an increase of 1.6% compared to RMB 1,406.2 million for the year ended December 31, 2023[2]. - The net profit for the year ended December 31, 2024, was RMB 88.5 million, a decrease of 48.8% from RMB 172.9 million recorded in 2023[2]. - Basic earnings per share for the year ended December 31, 2024, were RMB 0.63, down from RMB 1.17 in 2023[2]. - The gross profit for the year ended December 31, 2024, was RMB 663.4 million, a decrease of 4.1% from RMB 691.6 million in the previous year[6]. - The group achieved MDR CE certification for its hydrophilic acrylic intraocular lens product line, which is expected to lower costs and ensure long-term material supply[17]. - Total comprehensive income for the year was RMB 51,933,000, significantly lower than RMB 208,753,000 in 2023, a decline of approximately 75.1%[73]. - The company's total assets less current liabilities increased to RMB 2,054,497,000 in 2024 from RMB 1,952,050,000 in 2023, an increase of about 5.3%[75]. - Non-current liabilities rose to RMB 466,310,000 in 2024, compared to RMB 255,064,000 in 2023, reflecting an increase of approximately 83.0%[75]. - The group's total tax expense for the year 2024 is RMB 66,764,000, a decrease of 10.4% from RMB 74,821,000 in 2023[112]. - The effective tax rate for the group in 2024 is calculated at 43.0% based on the pre-tax profit of RMB 155,287,000, compared to 23.1% in 2023[113]. Revenue Breakdown - Revenue from the sale of ophthalmic medical consumables reached RMB 530.3 million, and revenue from technical services was RMB 226.5 million, both achieving historical highs[5]. - The company's proprietary products contributed RMB 375.8 million in revenue, a decrease of 1.6% from RMB 381.9 million in 2023[9]. - Technical services revenue increased by 8.3% to RMB 226.5 million, supported by a team of 133 engineers providing 24/7 service across Greater China[11]. - The self-owned products segment generated external sales of RMB 375,814,000, while the distribution products segment achieved RMB 819,321,000 in external sales[93]. - The technology services segment reported external sales of RMB 226,458,000, contributing to the overall revenue[93]. - Revenue from ophthalmic medical devices was RMB 664,878 thousand, down from RMB 680,271 thousand in 2023, representing a decrease of 2.0%[99]. - Revenue from ophthalmic medical consumables increased to RMB 530,257 thousand, up 3.9% from RMB 510,496 thousand in 2023[99]. Research and Development - The company has expanded its research and development capabilities with a "global 4+2" layout, including multiple platforms in China and two in Europe[4]. - R&D expenditure for the reporting period was RMB 78.4 million, representing 20.9% of self-owned product revenue, driven by increased investment in R&D projects to enhance independent innovation capabilities[12]. - Research and development expenses increased to RMB 78,418,000 in 2024 from RMB 52,883,000 in 2023, representing a rise of approximately 48.5%[71]. - The company plans to continue its focus on research and development in ophthalmic medical devices and consumables, aiming for market expansion in China and other regions[76]. - The group has a "global 4+2" R&D layout with 265 R&D personnel, accounting for approximately 30.0% of total employees, and an average of over ten years of industry experience[12]. Corporate Governance - The company has established an audit committee consisting of two independent non-executive directors and one non-executive director to oversee financial reporting and risk management[68]. - The company has committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[62]. - The company will continue to review and monitor its corporate governance practices to ensure compliance with applicable codes[65]. - The roles of Chairman and CEO were separated on March 25, 2024, with the appointment of a new CEO, Liu Xinwei[64]. - The company has a strong governance structure, including an audit committee and a board of directors to oversee its operations[140]. Market Expansion and Strategy - The group has established exclusive distribution agreements with 16 overseas brand partners, including a new partnership with South Korea's Sometech Inc. for 3D 4K digital ophthalmic surgical microscopes[15]. - The group’s products are sold in 52 countries and regions, with a focus on expanding market presence and product registration in new countries[17]. - The company is focused on developing and manufacturing its own products, particularly in the field of ophthalmology, including artificial lenses for cataract surgery[136]. - The company has a strategic plan to expand its market presence in the Greater China region, which includes mainland China, Hong Kong, Macau, and Taiwan[135]. - The company is actively engaging with key opinion leaders (KOLs) in the medical field to enhance its market influence and product adoption[136]. Financial Management - Cash and cash equivalents decreased by 31.9% from RMB 618.7 million as of December 31, 2023, to RMB 421.4 million as of December 31, 2024, primarily due to operational expenditures[43]. - The company has a total of RMB 507,728,000 in interest-bearing bank and other borrowings as of December 31, 2024, down from RMB 618,562,000 in 2023, a decrease of 18%[132]. - The company has secured a financing agreement for EUR 52.5 million to refinance existing loans, with a maturity date of December 22, 2027[133]. - The company maintains a diversified customer base for trade receivables, minimizing credit risk concentration[125]. - The company has implemented strict credit control measures to manage overdue receivables effectively[125]. Employee and Talent Management - As of December 31, 2024, the group had a total of 884 employees, an increase from 869 employees as of December 31, 2023[60]. - The total employee cost for the year ended December 31, 2024, was RMB 375.2 million, compared to RMB 352.5 million for the year ended December 31, 2023, reflecting an increase of approximately 6.1%[60]. - The company has adopted a share incentive plan to recognize and reward eligible participants for their contributions, aimed at attracting top talent[61]. - The company has implemented a training management system to enhance employee skills and support career development[60]. Dividend and Shareholder Returns - The company plans to propose a final dividend of HKD 0.3 per share for the year ended December 31, 2024, down from HKD 1.1 per share in 2023[2]. - The proposed final dividend per ordinary share for 2024 is HKD 0.30, significantly lower than HKD 1.10 in 2023, resulting in a total dividend payout of HKD 44,366,000 compared to HKD 162,767,000 in the previous year[112]. - The group paid a final dividend of RMB 148.5 million for the year ending December 31, 2023, and repaid loans totaling approximately RMB 109.7 million[44].

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 承董事會命 高視醫療科技有限公司 主席兼執行董事 高鐵塔先生 香港，2025年3月14日 於本公告日期，董事會包括主席兼執行董事高鐵塔先生，執行董事劉新偉先生、趙新禮先生、 張建軍先生及李文奇女士，非執行董事David Guowei Wang博士，以及獨立非執行董事馮昕先 生、王立新先生及陳帆城先生。 （股 份 代 號：2407） 董事會會議通告 高視醫療科技有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董 事」）會（「董事會」）謹此宣佈，董事會會議將於2025年3月26日（星期三）舉行， 藉以（其中包括）考慮及批准本集團截至2024年12月31日止年度的全年業績及其 發佈，並考慮建議派發末期股息（如有）。 ...